3/27/2023 0 Comments Silverback therapeutics![]() We are encouraged by the preclinical data and plan to initiate clinical investigation of SBT6050 later this year.” “Our preclinical data continue to highlight the potential for single agent clinical activity with SBT6050 even in tumors with diminished or absent T-cell infiltrates, and the opportunity for enhanced activity in combination with trastuzumab. ![]() “SBT6050 was designed to elicit a broad spectrum of anti-tumor immune responses through localized and potent activation of human myeloid cells,” said Valerie Odegard, Ph.D., Silverback’s chief scientific officer. These data demonstrate the potential for clinical activity with SBT6050 as a single agent and in combination with trastuzumab in the setting of moderate or high HER2-expressing malignancies. In a HER2-positive human xenograft model, a combination of low dose SBT6050 mouse surrogate with trastuzumab greatly enhanced the anti-tumor activity observed with either agent alone. ![]() Robust, durable single agent activity is observed with the SBT6050 mouse surrogate in multiple tumor models, including a human xenograft model lacking T, B, and NK cells, demonstrating the potential of myeloid cells to mediate strong anti-tumor activity. The presentation, titled “SBT6050, a HER2-Directed TLR8 Therapeutic, is a Systemically Administered, Tumor-Targeted Human Myeloid Cell Agonist,” shows that SBT6050 potently activates human myeloid cells in a HER2 dependent manner in vitro, and that an SBT6050 mouse surrogate exhibits potent anti-tumor efficacy as a single agent and in combination with trastuzumab in vivo. SEATTLE, WA, USA I I Silverback Therapeutics (“Silverback”), a biopharmaceutical company advancing a pipeline of therapies that are systemically delivered, but locally active, today announced that preclinical data for its lead ImmunoTAC™ candidate, SBT6050, will be presented at the ASCO Virtual Scientific Program at 8:00 a.m. Data to be presented at ASCO20 Virtual Scientific Program
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |